Measuring remission in schizophrenia: Response to Sethuraman et al., 2005 [3]

Schizophrenia Research

Volumn 83, Issue 1, 2006, Pages 109-110

  Kujawa, Mary ^a   Bossie, Cynthia A ^a   Lasser, Robert A ^b  

^a JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPSYCHOTIC AGENTS; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX;

EID: 33645377496     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2005.11.017     Document Type: Letter

References (5)

1. N.C. Andreasen, W.T. Carpenter Jr., J.M. Kane, R.A. Lasser, S.R. Marder, and D.R. Weinberger Remission in schizophrenia: proposed criteria and rationale for consensus Am. J. Psychiatry 162 2005 441 449
2. R.A. Lasser, C.A. Bossie, G.M. Gharabawi, and J.M. Kane Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection Schizophr. Res. 77 2005 215 227
3. J.A. Lieberman, M. Phillips, H. Gu, S. Stroup, P. Zhang, L. Kong, Z. Ji, G. Koch, and R.M. Hamer Atypical and conventional antipsychotic drugs in treatment-naïve first-episode schizophrenia: a 52-week randomized trial of clozapine vs. chlorpromazine Neuropsychopharmacology 28 2003 995 1003
4. G. Sethuraman, C.C. Taylor, M. Enerson, and E. Dunayevich A retrospective comparison of cumulative time spent in remission during treatment with olanzapine or risperidone among patients with schizophrenia Schizophr. Res. 79 2005 337 340
5. P.V Tran, S.H. Hamilton, A.J. Kuntz, J.H. Potvin, S.W. Andersen, C. Beasley Jr., and G.D. Tollefson Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders J. Clin. Psychopharmacol. 17 1997 407 418